Roche’s First Anti-TIGIT Data Support Dual Checkpoint Inhibition Strategy

May 15 2020

• By Mandy Jackson

Listen to this article

Tiragolumab plus Tecentriq increased response rates versus Tecentriq alone in a Phase II study, with the greatest benefit in PD-L1-high NSCLC. The combination regimen already is being test in Phase III.

Lungs operation puzzle concept: hands of surgeon with surgical instruments (tools) perform lungs surgery as a result of respiratory disease, pneumonia, tuberculosis, bronchitis, asthma, lung abscess — Tiragolumab plus Tecentriq worked best in PD-L1 high NSCLC • Source: Shutterstock

The first public data disclosure for Roche’s anti-TIGIT antibody tiragolumab in combination with the company’s PD-L1 inhibitor Tecentriq (atezolizumab) in first-line metastatic non-small cell lung cancer (NSCLC) showed improved response rates versus Tecentriq alone – including a notable improvement in high PD-L1-expressing tumors – and without adding significant toxicity.

The dual checkpoint inhibitor strategy could give Roche’s Tecentriq a critical boost in PD-1/L1 market share before competing combinations reach...

More from ASCO

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up
Jun 21 2024
• By Alaric DeArment
Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.
Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease
Jun 20 2024
• By Alaric DeArment
The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers.
ASCO 2024 Wrap-Up Podcast
Jun 19 2024
• By Alaric DeArment
Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.
China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights
Jun 16 2024
• By Brian Yang and Dexter Jie Yan
US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

More from Conferences

ESMO 24: NIAGARA – Trial Design Question Hangs Over Imfinzi’s Bladder Cancer Return
Sep 16 2024
• By Alexandra Shimmings
AstraZeneca’s NIAGARA trial of perioperative Imfinzi in bladder cancer was positively received at the ESMO meeting but its design did not distinguish the contributions of each treatment portion to the overall effect – something that the US FDA is likely to have a view on.
ESMO 24: Incyte’s Zynyz Finally Mounts The POD1UM
Sep 15 2024
• By Alexandra Shimmings
Persistence has paid off for Incyte’s Zynyz in anal cancer with a Phase III win that should make up for a previous disappointment at the FDA and give a boost to the firm’s pipeline prospects for a post-Jakafi era.
Sutro Works Toward A Better Ovarian Cancer ADC
Jul 04 2024
• By Mandy Jackson
Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.